Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma
2010-020454-34Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) and Myeloma bone disease (MBD) comparing Denosumab with Zoledronic acid (Zometa) (2 arms). Primary endpoint: Time to first on-study skeletal-related event (non-inferiority). Started May 2012; status: completed.
02
Drugs
denosumabzoledronic acid
03
Conditions
multiple myeloma (MM)Myeloma bone disease (MBD)
Beyond the preview
Go deeper on 2010-020454-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020454-34.